Dominari Holdings (Dominari Holdings) Cash And Cash Equivalents : $1.96 Mil (As of Mar. 2024)

View and export this data going back to 1984. Start your Free Trial

What is Dominari Holdings Cash And Cash Equivalents?

Dominari Holdings's quarterly cash and cash equivalents declined from Sep. 2023 ($4.39 Mil) to Dec. 2023 ($2.83 Mil) but then stayed the same from Dec. 2023 ($2.83 Mil) to Mar. 2024 ($1.96 Mil).

Dominari Holdings's annual cash and cash equivalents declined from Dec. 2021 ($65.56 Mil) to Dec. 2022 ($33.17 Mil) and declined from Dec. 2022 ($33.17 Mil) to Dec. 2023 ($2.83 Mil).

Dominari Holdings Cash And Cash Equivalents Historical Data

The historical data trend for Dominari Holdings's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dominari Holdings Cash And Cash Equivalents Chart

Dominari Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.09

2.72

65.56

33.17

2.83

Dominari Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															9.53	3.60	4.39	2.83	1.96

Dominari Holdings Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Dominari Holdings (NAS:DOMH) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Dominari Holdings Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Dominari Holdings's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Dominari Holdings (Dominari Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dominari Holdings Inc (NAS:DOMH) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

BP2A:Germany

Address

One Rockefeller Plaza, 11th Floor, New York, NY, USA, 10020

Website

https://www.dominariholdings.com

Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

Executives

Kyle Michael Wool	director	650 5TH AVE, 35TH FLOOR, NEW YORK NY 10019
Christopher Franklin Devall	officer: Chief Operating Officer	DOMINARI HOLDINGS INC., ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Anthony Hayes	director, officer: Chief Executive Officer	1796 SHADY LANE, COLUMBIA SC 29206
George Way	officer: Chief Financial Officer	C/O DOMINARI HOLDINGS INC., 725 5TH AVENUE 23RD FLOOR, NEW YORK NY 10022
Soo Yu	director	ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Tim S Ledwick	director	10200 INNOVATION DRIVE, SUITE 300, MILWAUKEE WI 53226
Gregory James Blattner	director	ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY 10020
Paul Lemire	director	ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Robert Frederick Dudley	director	ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Zanden Robert J Vander	director	913 HIGH KNOLL WAY, TRAVELERS REST SC 29690
Eric Weisblum	director	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Howard E Goldberg	director	781 THIRD AVENUE, KING OF PRUSSIA PA 194061409
Frank Reiner	officer: Interim CFO	6430 ROCKLEDGE DRIVE, SUITE 503, BETHESDA MD 20817
Jeffrey Ballabon	director	6430 ROCKLEDGE DRIVE, BETHESDA NY 20817
Richard Cohen	officer: Chief Financial Officer	C/O DUNE ENERGY, INC., TWO SHELL PLAZA, 777 WALKER STREET, SUITE 2300, HOUSTON TX 77002